EPISODE · Apr 28, 2026 · 11 MIN
Poolbeg Pharma: Sites ready, data due this summer — and Big Pharma is starting to knock
from Proactive - Interviews for investors · host Proactive Investors
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington joined Proactive's Stephen Gunnion to discuss the clinical-stage biopharmaceutical company's 2025 results and progress since then, highlighting a busy period for the company, with its lead POLB-001 trial now fully prepared to begin across six UK sites. The trial targets prevention of cytokine release syndrome - a serious complication of cancer immunotherapies - with patient screening imminent and interim data expected this summer. FDA orphan drug designation adds market exclusivity and financial incentives, while independent US payer research confirms multi-billion-dollar commercial potential and insurer willingness to reimburse. Partnering discussions with large and mid-sized pharma are intensifying ahead of the data readout. Skillington also flagged progress on an oral GLP-1 programme, with a proof-of-concept trial targeted for 2026. For more insights and interviews like this, visit Proactive’s YouTube channel, like this video, subscribe, and turn on notifications so you never miss an update. #PoolbegPharma #JeremySkillington #Biotech #ClinicalTrials #PharmaNews #CRS #CancerImmunotherapy #DrugDevelopment #HealthcareInnovation #GLP1 #Biopharma #Investing #StockMarket #SmallCapStocks #PharmaIndustry
What this episode covers
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington joined Proactive's Stephen Gunnion to discuss the clinical-stage biopharmaceutical company's 2025 results and progress since then, highlighting a busy period for the company, with its lead POLB-001 trial now fully prepared to begin across six UK sites. The trial targets prevention of cytokine release syndrome - a serious complication of cancer immunotherapies - with patient screening imminent and interim data expected this summer. FDA orphan drug designation adds market exclusivity and financial incentives, while independent US payer research confirms multi-billion-dollar commercial potential and insurer willingness to reimburse. Partnering discussions with large and mid-sized pharma are intensifying ahead of the data readout. Skillington also flagged progress on an oral GLP-1 programme, with a proof-of-concept trial targeted for 2026. For more insights and interviews like this, visit Proactive’s YouTube channel, like this video, subscribe, and turn on notifications so you never miss an update. #PoolbegPharma #JeremySkillington #Biotech #ClinicalTrials #PharmaNews #CRS #CancerImmunotherapy #DrugDevelopment #HealthcareInnovation #GLP1 #Biopharma #Investing #StockMarket #SmallCapStocks #PharmaIndustry
NOW PLAYING
Poolbeg Pharma: Sites ready, data due this summer — and Big Pharma is starting to knock
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.